164 related articles for article (PubMed ID: 35346570)
1. Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma.
Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P
Urol Oncol; 2022 May; 40(5):200.e1-200.e10. PubMed ID: 35346570
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.
Zapała Ł; Kunc M; Sharma S; Pęksa R; Popęda M; Biernat W; Radziszewski P
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4131-4139. PubMed ID: 36042047
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma.
Lee KS; Choe G; Yun S; Lee K; Moon S; Lee S; Hong SK; Byun SS; Lee SE
Histopathology; 2020 Jul; 77(1):67-78. PubMed ID: 31872892
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
6. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
10. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
12. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
14. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Ikeda J; Ohe C; Yoshida T; Ohsugi H; Sugi M; Tsuta K; Kinoshita H
Anticancer Res; 2021 Sep; 41(9):4577-4586. PubMed ID: 34475086
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
19. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
